Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Operating Leases: 2019-2025

Historic Operating Leases for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $55.2 million.

  • C4 Therapeutics' Operating Leases fell 10.11% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year decrease of 10.11%. This contributed to the annual value of $60.0 million for FY2024, which is 8.78% down from last year.
  • As of Q3 2025, C4 Therapeutics' Operating Leases stood at $55.2 million, which was down 2.83% from $56.9 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Operating Leases ranged from a high of $76.8 million in Q3 2022 and a low of $10.9 million during Q3 2021.
  • Its 3-year average for Operating Leases is $62.8 million, with a median of $62.9 million in 2024.
  • Per our database at Business Quant, C4 Therapeutics' Operating Leases skyrocketed by 602.87% in 2022 and then fell by 12.58% in 2023.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Operating Leases stood at $30.8 million in 2021, then spiked by 130.59% to $71.0 million in 2022, then declined by 7.35% to $65.8 million in 2023, then dropped by 8.78% to $60.0 million in 2024, then declined by 10.11% to $55.2 million in 2025.
  • Its Operating Leases stands at $55.2 million for Q3 2025, versus $56.9 million for Q2 2025 and $58.4 million for Q1 2025.